Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 Jun 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegfilgrastim (Primary)
Indications Febrile neutropenia
Focus Therapeutic Use
Acronyms PROTECT
Sponsors Amgen

Most Recent Events

13 Jun 2022 Results assessing incidence of febrile neutropenia in patients receiving pegfilgrastim, published in the Supportive Care in Cancer.
17 Nov 2016 Status changed from active, no longer recruiting to completed.
23 May 2016 Planned End Date changed from 1 Jan 2017 to 1 Oct 2018.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight